NAPPED: NAtural Course and Prognosis of PFIC and Effect of Biliary Diversion

Sponsor
University Medical Center Groningen (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT03930810
Collaborator
(none)
582
1
119.2
4.9

Study Details

Study Description

Brief Summary

The natural course of PFIC syndromes and the effect of diversion techniques, have so far not been characterized in a rigorous manner within a larger population of patients. In fact, the clinical or biochemical parameters which most directly define and/or predict the success of reduced enterohepatic circulation (either by surgical diversion or medically) are still unclear.

The present project aims to:
  1. Define the natural course of disease in genetically defined PFIC1, and PFIC2 patients, with respect to relevant biochemical and clinical parameters (and if available, histological). Included will be patients homozygous for a known, disease-causing mutation, patients compound homozygous for two disease-causing mutations or heterozygous for one disease-causing mutation in combination with the clinical phenotype of Bsep-deficiency or FIC1-deficiency.

  2. Define the change in the natural course of disease in response to biliary diversion surgery and or liver transplantation, based on short- and long(er)-term changes in biochemical (if available, histological) and clinical parameters, including outcome measures. Follow up after transplantation will be limited to max 3 months after transplant surgery, follow up after surgical biliary diversion will be as long as possible.

  3. Assessment of biochemical variables as possible surrogate endpoints for clinical hard endpoints. If possible this allows for identification of low-risk to high-risk patients early during follow-up.

  4. If patient numbers permit, to establish genotype-phenotype relationships for the most common genetic mutations causing Bsep-deficiency or FIC1-deficiency.

Based on this project it is anticipated that the investigators are able:
  • to characterize the variation in natural course of disease (whether or not genotype dependent) to allow clinicians to rationally select a target population for assessing the effect of medical intervention, rather than surgical biliary diversion);

  • to identify and qualify one or more biomarkers that independently predict either improved or poor clinical outcomes of surgical biliary diversion;

  • to investigate if the identified biomarker(s) can be used as surrogate end point(s) for assessing and predicting outcomes with novel interventional strategies.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Surgical biliary diversion

Study Design

Study Type:
Observational
Anticipated Enrollment :
582 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
NAtural Course and Prognosis of PFIC and Effect of Biliary Diversion (NAPPED Study), Meta-analysis of Individual Patient Data of PFIC Before and After Surgery (Bile Diversion or Liver Transplantation)
Actual Study Start Date :
Jan 26, 2017
Anticipated Primary Completion Date :
Jan 1, 2027
Anticipated Study Completion Date :
Jan 1, 2027

Arms and Interventions

Arm Intervention/Treatment
FIC1-deficiency and Bsep-deficiency

Procedure: Surgical biliary diversion
Surgical interruption of enterohepatic circulation

Outcome Measures

Primary Outcome Measures

  1. Number of participants with liver transplantation [at 18 years of age]

    Underwent liver transplant

  2. Number of participants that succumbed [at 18 years of age]

    Succumbed

Secondary Outcome Measures

  1. Number of participant undergoing a surgical biliary diversion [at 5, 10, 15 and 18 years of age]

    Underwent surgical biliary diversion

Eligibility Criteria

Criteria

Ages Eligible for Study:
0 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinical suspicion for Bsep- or FIC1-deficiency

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Medical Center Groningen Groningen Netherlands

Sponsors and Collaborators

  • University Medical Center Groningen

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Prof. Dr. Henkjan J. Verkade, Principal Investigator, Professor of Pediatrics, University Medical Center Groningen
ClinicalTrials.gov Identifier:
NCT03930810
Other Study ID Numbers:
  • METc2017.106
First Posted:
Apr 29, 2019
Last Update Posted:
May 3, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 3, 2021